Outlook Therapeutics, Inc.
OTLK · NASDAQ
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Revenue | $1,413,535,000 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1,356,330,000 | $114 | $44 | $205 |
| Gross Profit | $57,205,000 | -$114 | -$44 | -$205 |
| % Margin | 4% | – | – | – |
| R&D Expenses | $27,180,640,000 | $41,763 | $26,453 | $42,331 |
| G&A Expenses | $0 | $29,940 | $26,673 | $20,740 |
| SG&A Expenses | $39,938,231,000 | $29,940 | $26,673 | $20,740 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$205 |
| Operating Expenses | $67,118,871,000 | $71,703 | $53,126 | $62,866 |
| Operating Income | -$67,061,666,000 | -$71,703 | -$53,126 | -$63,071 |
| % Margin | -4,744.3% | – | – | – |
| Other Income/Exp. Net | $3,084,974,000 | -$3,661 | -$5,853 | -$2,978 |
| Pre-Tax Income | -$63,976,692,000 | -$75,364 | -$58,980 | -$66,049 |
| Tax Expense | -$1,551,829,000 | $3 | $3 | $3 |
| Net Income | -$62,424,863,000 | -$75,367 | -$58,983 | -$66,052 |
| % Margin | -4,416.2% | – | – | – |
| EPS | -1.79 | -4.06 | -4.72 | -6.23 |
| % Growth | 55.9% | 14% | 24.2% | – |
| EPS Diluted | -1.79 | -4.06 | -4.72 | -6.23 |
| Weighted Avg Shares Out | 34,796 | 18,549 | 12,508 | 10,604 |
| Weighted Avg Shares Out Dil | 25,476 | 18,549 | 12,508 | 10,604 |
| Supplemental Information | – | – | – | – |
| Interest Income | -$89,738,000 | $906 | $0 | $0 |
| Interest Expense | $283,128,000 | $3,157 | $1,560 | $1,487 |
| Depreciation & Amortization | $0 | $114 | $44 | $205 |
| EBITDA | -$67,061,666,000 | -$72,093 | -$57,376 | -$64,357 |
| % Margin | -4,744.3% | – | – | – |